2026 Q2 - tulosraportti
Vain PDF
36 päivää sitten
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 7 669 | AVA | NON | ||
| 2 272 | AVA | SSWM | ||
| 80 | AVA | SSWM | ||
| 29 828 | NON | AVA | ||
| 35 172 | NON | AVA |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 6.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 28.8. | ||
2026 Q1 - tulosraportti 22.5. | ||
2025 Q4 - tulosraportti 19.2. | ||
2025 Q3 - tulosraportti 12.11.2025 | ||
2025 Q2 - tulosraportti 29.8.2025 |
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·29.9.strong interest in Pexa
·7.9.I let Grok write a bit about the current situation from the ERS congress: What is actually happening on site PExA is exhibiting at the ERS International Congress 2026 in Fira Gran Via. Approx. 20,000 pulmonologists, researchers, and pharma people. On site: CEO Tomas Gustafsson, CTO Svante Höjer, and CSO Jörgen Östling. In the booth, they are also showing matched PEx–BAL samples and Small Airway Atlas. This is the quietest but perhaps most important thing: if the breath test correlates with BAL (the gold standard, but invasive), the sales argument against pharma becomes much stronger. Gustafsson said before departure, approximately: we are going there with stronger science, our biggest deal behind us, and completely different finances than a few months ago. Rumors circulating (ranked) 1. Who is the nameless top-10 company? This is the big buzz, and it has been in the air since June. PExA has a 7.5 Mkr / 18-month agreement with “one of the world’s ten largest pharmaceutical companies” for the rental of ten systems for an international IPF multicenter study. Delivery/installation was planned for Q3 2026 — i.e., now, around the congress. The name is still secret. Speculations follow two tracks: Roche — named partner in the P4O2 project COPD-PARASOL-ILD together with Amsterdam UMC, UMC Groningen, Utrecht, and PExA. The logic: they are already in the room. Boehringer Ingelheim — the IPF king at ERS (Ofev/nintedanib, plus nerandomilast data which is one of the congress's heavy themes). The logic: they have the most to gain from non-invasive fibrosis markers in clinical trials. Neither of the two is confirmed for the 7.5-million agreement. These are guesses. Other names appearing at the same time: AstraZeneca (previous PK collaboration via Fraunhofer), GSK, Novartis. 2. ERS as a sales tour, not a science show The company consists of three people. They are not a headline act at ERS — the big live events are about IL-33, TSLP, gene editing against AATD, and antifibrotics. PExA's play is that the three abstracts + the IPF order provide a reference when pharma and diagnostics companies visit hall X. The rumors among owners are not about them “winning the congress,” but about follow-up meetings that could lead to the next order. 3. PEx–BAL data in the booth This is whispered more in research circles than on stock forums. If they can show on the floor that PEx samples reflect BAL, it becomes an argument for replacing bronchoscopy in certain studies. It's not a stock driver in itself — but it's precisely the type of “site of action” pitch pharma wants to hear.
·24.8.Anders Hallberg, who took the directed issue, has an interesting track record. Was part of the fantastic Medivir journey and has now also entered Ortoma. The Pexa case is significantly strengthened now that Anders is involved.
·10.8.See clear potential in this company. Fantastic product. What do you here consider to be the commercial potential? It is currently sold to a relatively niche industry, research environments. In the long term, if this becomes a product in various labs, perhaps doctor's offices with their own laboratory, then this could become enormously big. Fire away with theories....
10.8.Same here. If this product is able to deliver on its promises, I see it being prevalent in both private/university hospitals - respiratory departments and in occupational medicine- as well as in doctors offices worldwide. It has the potential to replace bronchoscopy and bronchoalveolar lavage, both of which are quite invasive and more expensive to perform (needing some kind of sedation, sometimes even general anesthesia), not to mention the usefulness to diagnose a wide range of pathologies.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
Vain PDF
36 päivää sitten
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·29.9.strong interest in Pexa
- ·7.9.I let Grok write a bit about the current situation from the ERS congress: What is actually happening on site PExA is exhibiting at the ERS International Congress 2026 in Fira Gran Via. Approx. 20,000 pulmonologists, researchers, and pharma people. On site: CEO Tomas Gustafsson, CTO Svante Höjer, and CSO Jörgen Östling. In the booth, they are also showing matched PEx–BAL samples and Small Airway Atlas. This is the quietest but perhaps most important thing: if the breath test correlates with BAL (the gold standard, but invasive), the sales argument against pharma becomes much stronger. Gustafsson said before departure, approximately: we are going there with stronger science, our biggest deal behind us, and completely different finances than a few months ago. Rumors circulating (ranked) 1. Who is the nameless top-10 company? This is the big buzz, and it has been in the air since June. PExA has a 7.5 Mkr / 18-month agreement with “one of the world’s ten largest pharmaceutical companies” for the rental of ten systems for an international IPF multicenter study. Delivery/installation was planned for Q3 2026 — i.e., now, around the congress. The name is still secret. Speculations follow two tracks: Roche — named partner in the P4O2 project COPD-PARASOL-ILD together with Amsterdam UMC, UMC Groningen, Utrecht, and PExA. The logic: they are already in the room. Boehringer Ingelheim — the IPF king at ERS (Ofev/nintedanib, plus nerandomilast data which is one of the congress's heavy themes). The logic: they have the most to gain from non-invasive fibrosis markers in clinical trials. Neither of the two is confirmed for the 7.5-million agreement. These are guesses. Other names appearing at the same time: AstraZeneca (previous PK collaboration via Fraunhofer), GSK, Novartis. 2. ERS as a sales tour, not a science show The company consists of three people. They are not a headline act at ERS — the big live events are about IL-33, TSLP, gene editing against AATD, and antifibrotics. PExA's play is that the three abstracts + the IPF order provide a reference when pharma and diagnostics companies visit hall X. The rumors among owners are not about them “winning the congress,” but about follow-up meetings that could lead to the next order. 3. PEx–BAL data in the booth This is whispered more in research circles than on stock forums. If they can show on the floor that PEx samples reflect BAL, it becomes an argument for replacing bronchoscopy in certain studies. It's not a stock driver in itself — but it's precisely the type of “site of action” pitch pharma wants to hear.
- ·24.8.Anders Hallberg, who took the directed issue, has an interesting track record. Was part of the fantastic Medivir journey and has now also entered Ortoma. The Pexa case is significantly strengthened now that Anders is involved.
- ·10.8.See clear potential in this company. Fantastic product. What do you here consider to be the commercial potential? It is currently sold to a relatively niche industry, research environments. In the long term, if this becomes a product in various labs, perhaps doctor's offices with their own laboratory, then this could become enormously big. Fire away with theories....10.8.Same here. If this product is able to deliver on its promises, I see it being prevalent in both private/university hospitals - respiratory departments and in occupational medicine- as well as in doctors offices worldwide. It has the potential to replace bronchoscopy and bronchoalveolar lavage, both of which are quite invasive and more expensive to perform (needing some kind of sedation, sometimes even general anesthesia), not to mention the usefulness to diagnose a wide range of pathologies.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 7 669 | AVA | NON | ||
| 2 272 | AVA | SSWM | ||
| 80 | AVA | SSWM | ||
| 29 828 | NON | AVA | ||
| 35 172 | NON | AVA |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 6.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 28.8. | ||
2026 Q1 - tulosraportti 22.5. | ||
2025 Q4 - tulosraportti 19.2. | ||
2025 Q3 - tulosraportti 12.11.2025 | ||
2025 Q2 - tulosraportti 29.8.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
Vain PDF
36 päivää sitten
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 6.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 28.8. | ||
2026 Q1 - tulosraportti 22.5. | ||
2025 Q4 - tulosraportti 19.2. | ||
2025 Q3 - tulosraportti 12.11.2025 | ||
2025 Q2 - tulosraportti 29.8.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·29.9.strong interest in Pexa
- ·7.9.I let Grok write a bit about the current situation from the ERS congress: What is actually happening on site PExA is exhibiting at the ERS International Congress 2026 in Fira Gran Via. Approx. 20,000 pulmonologists, researchers, and pharma people. On site: CEO Tomas Gustafsson, CTO Svante Höjer, and CSO Jörgen Östling. In the booth, they are also showing matched PEx–BAL samples and Small Airway Atlas. This is the quietest but perhaps most important thing: if the breath test correlates with BAL (the gold standard, but invasive), the sales argument against pharma becomes much stronger. Gustafsson said before departure, approximately: we are going there with stronger science, our biggest deal behind us, and completely different finances than a few months ago. Rumors circulating (ranked) 1. Who is the nameless top-10 company? This is the big buzz, and it has been in the air since June. PExA has a 7.5 Mkr / 18-month agreement with “one of the world’s ten largest pharmaceutical companies” for the rental of ten systems for an international IPF multicenter study. Delivery/installation was planned for Q3 2026 — i.e., now, around the congress. The name is still secret. Speculations follow two tracks: Roche — named partner in the P4O2 project COPD-PARASOL-ILD together with Amsterdam UMC, UMC Groningen, Utrecht, and PExA. The logic: they are already in the room. Boehringer Ingelheim — the IPF king at ERS (Ofev/nintedanib, plus nerandomilast data which is one of the congress's heavy themes). The logic: they have the most to gain from non-invasive fibrosis markers in clinical trials. Neither of the two is confirmed for the 7.5-million agreement. These are guesses. Other names appearing at the same time: AstraZeneca (previous PK collaboration via Fraunhofer), GSK, Novartis. 2. ERS as a sales tour, not a science show The company consists of three people. They are not a headline act at ERS — the big live events are about IL-33, TSLP, gene editing against AATD, and antifibrotics. PExA's play is that the three abstracts + the IPF order provide a reference when pharma and diagnostics companies visit hall X. The rumors among owners are not about them “winning the congress,” but about follow-up meetings that could lead to the next order. 3. PEx–BAL data in the booth This is whispered more in research circles than on stock forums. If they can show on the floor that PEx samples reflect BAL, it becomes an argument for replacing bronchoscopy in certain studies. It's not a stock driver in itself — but it's precisely the type of “site of action” pitch pharma wants to hear.
- ·24.8.Anders Hallberg, who took the directed issue, has an interesting track record. Was part of the fantastic Medivir journey and has now also entered Ortoma. The Pexa case is significantly strengthened now that Anders is involved.
- ·10.8.See clear potential in this company. Fantastic product. What do you here consider to be the commercial potential? It is currently sold to a relatively niche industry, research environments. In the long term, if this becomes a product in various labs, perhaps doctor's offices with their own laboratory, then this could become enormously big. Fire away with theories....10.8.Same here. If this product is able to deliver on its promises, I see it being prevalent in both private/university hospitals - respiratory departments and in occupational medicine- as well as in doctors offices worldwide. It has the potential to replace bronchoscopy and bronchoalveolar lavage, both of which are quite invasive and more expensive to perform (needing some kind of sedation, sometimes even general anesthesia), not to mention the usefulness to diagnose a wide range of pathologies.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 7 669 | AVA | NON | ||
| 2 272 | AVA | SSWM | ||
| 80 | AVA | SSWM | ||
| 29 828 | NON | AVA | ||
| 35 172 | NON | AVA |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Välittäjätilasto
Dataa ei löytynyt